Figure 6
From: Engineering of chimeric peptides as antagonists for the G protein-coupled receptor, RXFP4
Antagonist activity of novel chimeric analogue 17 compared with ΔR3/I5 in RXFP3 and RXFP4 cells. (A) Ability of ΔR3/I5 and analogues 17 to antagonize 10 nM analogue 2-induced inhibition of cAMP activity. (B) Ability of ΔR3/I5 and analogues 17 to antagonize 16.6 nM analogue 13-induced inhibition of cAMP activity. The data are the result of n = 3–4 independent experiments and are expressed as mean ± SEM.
